Erratum: Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: Results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies (Journal of Viral Hepatitis DOI: 10.1111/jvh.12365);Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: Results from 1161 patients in the QUEST-1, QUEST-2 and PROMISE studies

Journal of Viral Hepatitis

Volumn 22, Issue 8, 2015, Pages 639-650

  Scott, J ^a   Gilles, L ^b   Fu, M ^c   Brohan, E ^d   Panter, C ^d   Arbuckle, R ^d   Jessner, W ^b   Beumont, M ^b  

^a Janssen Global Services LLC   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d ADELPHI REAL WORLD   (United Kingdom)

Author keywords

chronic hepatitis C; daily functioning; depressive symptoms; fatigue; health related quality of life; simeprevir

Indexed keywords

PEGINTERFERON; PLACEBO; RIBAVIRIN; SIMEPREVIR; INTERFERON;

ADULT; AGED; ANALYTIC METHOD; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; ADOLESCENT; COMPLICATION; DOUBLE BLIND PROCEDURE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPATITIS C, CHRONIC; INCIDENCE; LIVER; MIDDLE AGED; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANEMIA; DEPRESSION; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FATIGUE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; INTERFERONS; LIVER; MALE; MIDDLE AGED; PLACEBOS; RIBAVIRIN; SIMEPREVIR; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84934853289     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12523     Document Type: Erratum

References (43)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, et al,. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB,. American Association for the Study of Liver Disease. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49 (4): 1335-1374.
3. Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F,. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis 2012; 12 (Suppl 2): S2.
4. Vietri J, Prajapati G, El Khoury AC,. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol 2013; 13: 16.
5. Dan AA, Martin LM, Crone C, et al,. Depression, anemia and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44 (3): 491-498.
6. Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ,. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49 (5): 311-317.
7. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok AS,. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. J Hepatol 2002; 36 (3): 401-407.
8. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G,. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96 (7): 2199-2205.
9. Blackburn S, McCool R, Panter C, et al,. Interviews with patients with chronic hepatitis C (CHC) virus infection document unmet needs, content validity, and comprehension of pros for clinical trials. Value Health 2013; 16 (3): A6.
10. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54 (4): 1433-1444.
11. Leroy V, Serfaty L, Bourlière M, et al,. Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver. Liver Int 2012; 32 (10): 1477-1492.
12. ™ (Telaprevir). US prescribing information 2013. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ed0e4f33-cf21-4fe3-918d-1d5b3a23eee4#section-8.1. Accessed 31 March 2014
13. ™ (Boceprevir). US prescribing information 2013. Available from: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae879ebe-b620-4829-b6f8-74b58da1c771#section-7.1. Accessed 31 March 2014.
14. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.
15. Hadziyannis SJ, Sette H Jr, Morgan TR, et al,. Peginterferon-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140 (5): 346-355.
16. Kauf TL, Mohamed AF, Hauber AB, Fetzer D, Ahmad A,. Patients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection. Patient 2012; 5 (4): 265-278.
17. Fried M, Buti M, Dore G, et al,. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-Naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58 (6): 1918-1929.
18. Zeuzem S, Berg T, Gane E, et al,. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146 (2): 430-441.
19. Jacobson I, Dore GJ, Foster GR, et al,. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384 (9941): 403-413.
20. Manns M, Marcellin P, Poordad F, et al,. Simeprevir (TMC435) with peginterferon α-2a or α-2b/ribavirin for the treatment of chronic HCV genotype 1 infection in treatment-naive patients: QUEST-2, a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2014; 384 (9941): 414-426.
21. Forns X, Lawitz E, Zeuzem S, et al,. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a Phase 3 trial. Gastroenterology 2014; 146 (7): 1669-1679.e3.
22. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2013; 310 (20): 2191-2194.
23. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD,. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46 (10): 1121-1123.
24. McHutchison JG, Manns MP, Muir AJ, et al,. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362 (14): 1292-1303.
25. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J,. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35 (3): 704-708.
26. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH,. Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010; 12: R177.
27. Manns M, Fried M, Zeuzem S, et al,. Simeprevir with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection: pooled safety analysis from Phase IIb and III studies. J Viral Hepatitis 2014; [Epub ahead of print].
28. McLernon DJ, Dillon J, Donnan PT,. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008; 28 (4): 582-592.
29. Lerdal A, Wahl AK, Rustoen T, Hanestad BR, Moum T,. Fatigue in the general population: a translation and test of the psychometric properties of the Norwegian version of the fatigue severity scale. Scand J Public Health 2005; 33 (2): 123-130.
30. Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR,. Validation of the fatigue severity scale in a Swiss cohort. Sleep 2008; 31 (11): 1601-1607.
31. Kleinman L, Zodet MW, Hakim Z, et al,. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000; 9 (5): 499-508.
32. Radloff LS,. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1 (3): 385-401.
33. Clark CH, Mahoney JS, Clark DJ, Eriksen LR,. Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs 2002; 40 (3): 361-369.
34. Dbouk N, Arguedas MR, Sheikh A,. Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci 2008; 53 (4): 1100-1106.
35. Reilly M, Zbrozek A, Dukes E,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4 (5): 353-365.
36. El Khoury A, Vietri J, Prajapati G,. The burden of untreated hepatitis C virus infection: a US patients perspective. Dig Dis Sci 2012; 57 (11): 2995-3003.
37. DiBonaventura MD, Wagner JS, Yuan Y, L'Italien G, Langley P, Ray KW,. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 2011; 14 (2): 253-261.
38. DiBonaventura MD, Yuan Y, Wagner JS, L'Italien GJ, Lescrauwaet B, Langley P,. The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. Eur J Gastro Hepatol 2012; 24 (8): 869-877.
39. Liu GG, DiBonaventura MD, Yuan Y, Wagner J-S, L'Italien GJ, Langley P,. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health 2012; 15 (1 Suppl): S65-S71.
40. Group TE. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (3): 199-208.
41. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ,. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005; 76 (1): 58-63.
42. Brazier J, Jones N, Kind P,. Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2 (3): 169-180.
43. Chong CA, Gulamhussein A, Heathcote EJ, et al,. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98 (3): 630-638.